Skip to main content

Clinical Trials Using Rituximab

Review the clinical trials studying rituximab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-100 of 120

Zanubrutinib with R-CHOP for the Treatment of Patients with Diffuse Large B-Cell Lymphoma
Status: Active
Location: VCU Massey Comprehensive Cancer Center, Richmond, Virginia
Mini Hyper-CVD with Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for the Treatment of Relapsed B-Cell Acute Lymphocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) with or without Rituximab plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
Epcoritamab with Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Epcoritamab in Combination with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-miniCVP) for Older, Unfit and Frail Patients or Anthracycline-Ineligible Patients with Diffuse Large B-Cell Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Alpha/Beta T Cell Depleted Stem Cell Transplant in Treating Patients with Fanconi Anemia or Telomere Biology Disorder
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Asparaginase Erwinia Chrysanthemi with Chemotherapy for the Treatment of High-Risk Adults with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Dose-Adjusted EPOCH with or without Rituximab plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients with B Acute Lymphoblastic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Chemotherapy and Cord Blood Transplant in Children and Young Adults with Blood Cancers or Non-malignant Disorders
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Pirtobrutinib in Combination with Rituximab for Controlling Disease in Patients with Newly Diagnosed Low or Intermediate Risk Mantle Cell Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, Clonal Cytopenia of Undetermined Significance and Chronic Myelomonocytic Leukemia
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Personalized NK Cell Therapy after Chemotherapy and Cord Blood Transplant in Treating Patients with Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Polatuzumab Vedotin and Rituximab With or Without Chemotherapy for the Treatment of Post-Transplant Lymphoproliferative Disorder
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Valemetostat in Combination with Lenalidomide and Rituximab for the Treatment of Grade 1-3a Relapsed or Refractory Follicular Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
iC9 CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells and Lymphodepleting Chemotherapy for the Treatment of Relapsed or Refractory T-cell Leukemia or Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients with Acute Lymphoblastic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Capivasertib, Venetoclax, and Low-Intensity Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma, CAVALRY Trial
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Bendamustine with or without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
CC-99282 and Rituximab for the Treatment of Patients who have Received CAR T-Cell Therapy for Relapsed or Refractory Non-Hodgkin's Lymphoma
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Loncastuximab Tesirine and Rituximab after Stereotactic Radiosurgery for the Treatment of Primary and Secondary Central Nervous System Lymphomas, SOLAR Trial
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Intraventricular CARv3-TEAM-E T Cells for the Treatment of Patients with Glioblastoma, INCIPIENT Study
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts